BiotechTube

OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Inflammation Corneal

Conditions

Inflammation Corneal, Pain, Postoperative

Trial Timeline

Sep 27, 2019 → Jan 31, 2020

NCT ID
NCT04130802

About OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo

OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo is a phase 2 stage product being developed by Oculis Holding AG for Inflammation Corneal. The current trial status is completed. This product is registered under clinical trial identifier NCT04130802. Target conditions include Inflammation Corneal, Pain, Postoperative.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04130802Phase 2Completed

Competing Products

20 competing products in Inflammation Corneal

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303Sun PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterolMerckPhase 1
33
MAS825 + PlaceboNovartisPhase 2
52
Secukinumab s.c. injectionNovartisApproved
85
etanerceptAmgenPhase 3
76
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0114-0006 + placeboNovo NordiskPhase 2
51
NNC0114-0006 + placeboNovo NordiskPhase 1
32
NNC0109-0012 + placeboNovo NordiskPhase 2
51
NNC 0151-0000-0000 + NNC 0151-0000-0000 + placeboNovo NordiskPhase 1
32
catridecacog + placeboNovo NordiskPhase 2
51
NNC109-0012 + placeboNovo NordiskPhase 2
51
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0215-0384 + placeboNovo NordiskPhase 1
32
NNC 0151-0000-0000 + placeboNovo NordiskPhase 2
51

Other Products from Oculis Holding AG

OCS-01 + VehiclePhase 3
72
Dexamethasone Ophthalmic SuspensionPhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 2/3
60
OCS-01Phase 2
47